| Gene | Score gda | Association Type | Type | Original DB | Sentence supporting the association | PMID | PMID Year | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
0.400 | GeneticVariation | group | BEFREE | MET exon 14 skipping and missense mutations were identified in two (11.1%) cases with adenocarcinoma histology. | 29489023 | 2018 | ||||
|
0.400 | Biomarker | group | BEFREE | Subgroup analyses suggest that high MET CNG is associated with a worse prognosis, especially in patients with adenocarcinoma and Asian populations. | 29805710 | 2018 | ||||
|
0.400 | GeneticVariation | group | BEFREE | CUP adenocarcinomas and poorly differentiated carcinomas harboured the highest frequency of variants in genes involved in signal transduction pathways (e.g.MET, EGFR, HRAS, KRAS, and BRAF). | 29973234 | 2018 | ||||
|
0.400 | Biomarker | group | BEFREE | Although MET amplification-positive tumor is considered aggressive, our results suggest that it has a more favorable prognosis than amplification-negative cases in stage IV pulmonary adenocarcinoma with medical treatment. | 31329925 | 2019 | ||||
|
0.400 | AlteredExpression | group | BEFREE | High MET protein expression was detected in 25% (193/763), and was significantly more common in adenocarcinomas than squamous cell carcinoma (P<0.01). | 31106127 | 2019 | ||||
|
0.400 | Biomarker | group | BEFREE | Sanchez-Vega and colleagues prospectively demonstrate that both intra- and intertumoral differential expression of the receptor tyrosine kinases HER2, EGFR, and MET dictate sensitivity to the pan-HER inhibitor afatinib in a phase II trial of trastuzumab-refractory <i>HER2</i>-amplified gastroesophageal adenocarcinomas. | 30737213 | 2019 | ||||
|
0.400 | Biomarker | group | BEFREE | In the subgroup of adenocarcinoma and squamous cell carcinoma patients with stage IIA-IIIB disease, the prognostic impact of c-MET was significant in the univariate analysis (HR = 0.60, 95% CI: 0.43-0.83). | 31200831 | 2019 | ||||
|
0.400 | Biomarker | group | BEFREE | The MET gene had increased copy numbers in 9.88% of the NSCL adenocarcinoma patients; 3.49% of MET mutations in NSCL adenocarcinoma included 3 intron mutations. | 28952227 | 2019 |